Financial Performance - Operating revenue for the first nine months of 2024 was CNY 89,245,304.80, down 22.50% year-over-year[3]. - Net profit attributable to shareholders for the first nine months of 2024 was a loss of CNY 16,117,302.93, representing a 156.06% increase in loss compared to the same period last year[3]. - The company recorded a net loss of CNY 16,117,302.93 for the current year, primarily due to decreased operating revenue and increased management costs[5]. - Total operating revenue for the first nine months of 2024 was ¥89,245,304.80, a decrease of 22.5% compared to ¥115,156,370.54 in the same period of 2023[21]. - Operating profit for the first nine months of 2024 was -¥16,087,529.89, compared to -¥6,109,030.26 in the same period of 2023, indicating a worsening of 163.5%[22]. - Net profit for the first nine months of 2024 was -¥16,117,302.93, compared to -¥6,294,345.42 in the same period of 2023, reflecting an increase in losses of 156.5%[22]. - The total comprehensive income for the period was -¥15,048,335.49, compared to -¥5,317,980.32 in the same period last year[24]. Assets and Liabilities - Total assets as of September 30, 2024, were CNY 401,438,503.20, a decrease of 5.26% compared to the end of the previous year[3]. - The company's current assets total 69,519,860.54, a decrease from 80,413,784.74 in the previous year[15]. - The company's inventory has decreased from 30,789,663.07 to 22,978,526.59, indicating a reduction of approximately 25.5%[15]. - Fixed assets have increased significantly from 159,187,288.72 to 290,700,115.04, reflecting a growth of approximately 82.5%[15]. - Current liabilities decreased from 80.14 billion to 76.54 billion, a reduction of about 4.0%[16]. - Non-current liabilities decreased from 26.26 billion to 23.70 billion, a decrease of approximately 9.7%[16]. - Total liabilities decreased from 106.40 billion to 100.25 billion, a decline of around 5.4%[17]. - Shareholders' equity decreased from 317.31 billion to 301.19 billion, a reduction of about 5.1%[17]. Cash Flow - The net cash flow from operating activities for the first nine months of 2024 was CNY 14,062,426.82, an increase of 2,820.43% year-over-year[3]. - The net cash flow from operating activities for the first nine months of 2024 was ¥14,062,426.82, compared to a negative cash flow of ¥516,918.53 in the same period of 2023[26]. - Total cash inflow from operating activities was ¥103,535,818.11, down 16.3% from ¥123,743,294.55 in the previous year[25]. - The net cash flow from investing activities was -¥6,886,536.20, significantly improved from -¥33,349,200.10 in the same period last year[26]. - Cash inflow from financing activities decreased to ¥65,000,000.00 from ¥113,000,000.00 year-over-year, a decline of 42.5%[26]. - The total cash outflow from operating activities was ¥89,473,391.29, down from ¥124,260,213.08 year-over-year[25]. - The company’s cash flow from financing activities resulted in a net outflow of -¥7,127,260.05, compared to a net inflow of ¥12,861,343.35 in the previous year[26]. Shareholder Information - The total number of ordinary shares at the end of the reporting period is 111,360,400, with 62.36% being freely tradable shares[8]. - The largest shareholder, Yan Heping, holds 53,246,000 shares, representing 47.81% of the total shares[9]. - The number of shareholders holding more than 5% of shares has increased to 10, with a total holding of 72,785,678 shares, representing 65.36% of total shares[9]. Expenses - Management expenses increased by 29.71% to CNY 20,376,309.51, primarily due to depreciation costs from new production lines[4]. - Research and development expenses for the first nine months of 2024 were ¥6,643,893.80, a decrease of 14.3% from ¥7,749,700.05 in the same period of 2023[21]. - Sales expenses decreased to ¥11,352,942.59 from ¥14,164,333.56, a reduction of 19.7%[21]. - Tax expenses increased to ¥1,209,822.09 from ¥810,219.72, an increase of 49.2%[21]. - Other income increased to ¥4,305,456.31 from ¥3,955,979.67, an increase of 8.8%[21]. Other Information - The company has no major litigation or arbitration matters reported during the period[11]. - The company has engaged in related party transactions, with a total expected amount of 213,000,000, of which 29,000,000 has been executed[12]. - The company has pledged assets totaling 93,966,865.82, which accounts for 23.41% of total assets[14]. - The company has fulfilled all disclosed commitments without any overdue obligations during the reporting period[13]. - Non-recurring gains and losses totaled CNY 4,230,542.76, reflecting various adjustments and government subsidies[6].
大禹生物(871970) - 2024 Q3 - 季度财报